(12) Patent Application Publication (10) Pub. No.: US 2014/0005219 A1 Foster Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2014/0005219 A1 Foster Et Al US 2014.0005219A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0005219 A1 Foster et al. (43) Pub. Date: Jan. 2, 2014 (54) INTRATHECAL HYDROMORPHONE (60) Provisional application No. 61/607,774, filed on Mar. SOLUTIONS HAVING IMPROVED 7, 2012. STABILITY Publication Classification (71) Applicant: Mallinckrodt LLC, Hazelwood, MO (51) Int. Cl. (US) A613 L/485 (2006.01) (72) Inventors: John J. Foster, St. Paul, MN (US); (52) U.S. Cl. Thomas R. Prentice, St. Paul, MN (US) CPC .................................... A6 IK3I/485 (2013.01) USPC .......................................................... S14/282 (21) Appl. No.: 14/019,828 (57) ABSTRACT The present disclosure relates generally to a pharmaceutical (22) Filed: Sep. 6, 2013 Solution comprising hydromorphone or a pharmaceutically acceptable salt thereofthat is substantially free of buffer and optionally one or more other additives. The pharmaceutically Related U.S. Application Data acceptable salt may be hydromorphone hydrochloride. Also (63) Continuation-in-part of application No. 13/787,042, disclosed are methods for the manufacture and use of the filed on Mar. 6, 2013. Solution. Patent Application Publication Jan. 2, 2014 Sheet 2 of 2 US 2014/0005219 A1 FIG. 2 US 2014/0005219 A1 Jan. 2, 2014 INTRATHECAL HYDROMORPHONE with relative levels of some liver enzymes being the main SOLUTIONS HAVING IMPROVED cause; the normal human range appears to be from 8:1 to a STABILITY little under 4:1. It is not uncommon, for example, for the 8-mg tablet to have an effect similar to 30 mg of morphine sulfate or CROSS REFERENCE TO RELATED a similar morphine preparation. APPLICATIONS 0007. The currently available hydromorphone hydrochlo 0001. This application is a continuation-in-part of prior ride solutions all contain buffer. The buffer is often added to U.S. patent application Ser. No. 13/787,042, filed Mar. 6, a composition to regulate the pH and/or aid in the stability of the compound in solution. The addition of buffer can lead to 2013, which claims the benefit of priority of U.S. Provisional potential complications. Such as toxicity or other side effects, Application No. 61/607,774, filed Mar. 7, 2012. allergic responses and/or granuloma formation. Further, the BACKGROUND OF THE DISCLOSURE use of less or no buffer would decrease the costs of producing the pharmaceutical composition and reduce manufacturing 0002 The present disclosure relates generally to a sterile complexity. Currently available hydromorphone hydrochlo Solution of hydromorphone and/or one or more pharmaceu ride Solutions also have not been approved for intrathecal use. tically acceptable salts thereof that is substantially free of Accordingly, there is a need for a hydromorphone hydrochlo buffer and optionally one or more other additives. For ride solution that does not contain buffer, and is suitable for example, in one aspect, the present disclosure relates to a intrathecal use. Surprisingly, it has been found that hydro sterile hydromorphone hydrochloride solution that is sub morphone hydrochloride, as well as other hydromorphone stantially free of buffer and other additives. salts, in water do not require buffering agents to maintain 0003 Hydromorphone hydrochloride is a narcotic analge stability over time. sic, and one of its principle uses is the relief of pain. It is a 0008. Additionally, there has been increasing interest semi-synthetic L-opioid agonist. There is no intrinsic limit to recently in the regulation of the cerebrospinal fluid (CSF) pH. the analgesic effect of hydromorphone hydrochloride; like Part of this interest stems from the fact that the extracellular morphine, adequate doses will relieve even the most severe fluid (ECF) pH in the brain serves as an important regulator of pain. Hydromorphone is the generic (USAN) name (USP pulmonary ventilation and a major determinant of cerebral Dictionary of USAN and International Drug Names 2003) for blood flow. Furthermore, since the CSF pH has been shown to 4.5-O-epoxy-3-hydroxy-17-methyl morphinan-6-one, a be subject to a considerable degree of homeostatic control in derivative of morphine. Its structural formula is: a variety of conditions which change the acid-base status of blood, many attempts have been made to unravel the physi ological mechanisms which are responsible for this control. Finally, since the acid-base metabolism of the cerebral com N partments (including the ECF) may influence cerebral func tion to a significant degree, the CSF pH and the mechanisms which regulate it have become of concern to neurologists and neurosurgeons. CSF normally has a pH near 7.3. Since intrathecal delivery of hydromorphone hydrochloride is direct injection into the CSF, and it is desirable to keep the pH of the resulting CSF hydromorphone solution mixture as close to 7.3 as possible, injection of a hydromorphone hydro chloride formulation with a pH near 7.3 is appealing. Advan 0004 Presently, intrathecal hydromorphone hydrochlo tageously, the pH of the formulation without buffer is closer ride is commercially available for injection in 10 mg/ml solu to the natural physiological pH of CSF than the formulation tions in a preservative-free formula containing 0.2% sodium containing buffer (5.0 vs. 4.1). citrate and 0.2% of a citric acid solution. BRIEF DESCRIPTION OF THE DISCLOSURE 0005 Hydromorphone is used in medicine as an alterna tive to morphine and diacetylmorphine for analgesia and as a 0009. In one aspect, the present disclosure is directed to a second- or third-line narcotic antitussive (cough suppressant) sterile pharmaceutical Solution comprising hydromorphone, for cases of dry, painful, paroxysmal coughing resulting from a pharmaceutically acceptable salt(s) thereof, or combina continuing bronchial irritation after influenza and other ail tions thereof, wherein the solution is substantially free of ments, inhalation of fungus and other causes, and is generally buffer and optionally one or more other additives. In one regarded to be the strongest of the latter class of drugs, and particular embodiment, the solution comprises hydromor was developed shortly after another powerful antitussive, phone hydrochloride. heroin, was removed from clinical use for this purpose in 0010. Another aspect of the present disclosure is a sterile most of the world and in many countries banned outright. pharmaceutical Solution consisting essentially of hydromor 0006. The hydrogenation of morphine resulting in the for phone and/or a pharmaceutically acceptable salt(s) thereof mation of hydromorphone results in a drug with higher lipid and water. In one particular embodiment, the pharmaceuti solubility and ability to cross the blood-brain barrier and cally acceptable salt is hydromorphone hydrochloride. therefore more rapid and complete central nervous system 0011 Yet another aspect of the present disclosure is a penetration, with the result that hydromorphone is somewhat sterile pharmaceutical Solution consisting of hydromorphone faster-acting and about eight times stronger than morphine and/or a pharmaceutically acceptable salt(s) thereof (e.g., and about three times stronger than heroin on a milligram hydromorphone hydrochloride) and water. basis. The effective morphine to hydromorphone conversion 0012. A further aspect of the disclosure provides a method ratio can vary from patient to patient by a significant amount for manufacturing a pharmaceutical Solution, the method US 2014/0005219 A1 Jan. 2, 2014 comprising (i) combining hydromorphone, a pharmaceuti a hydromorphone solution containing buffer, thus provide an cally acceptable salt(s) thereof, or combinations thereof with unexpected advantage over hydromorphone solutions con sterile water in the absence of buffers and/or other additives, taining buffers. and (ii) dissolving the hydromorphone and/or the pharmaceu 0020. Additionally, since hydromorphone solutions of the tically acceptable salt(s) thereof to form the solution. In one present disclosure are intended for intrathecal administration, particular embodiment, the pharmaceutically acceptable salt it is also desirable for the pH of the solutions to be sufficiently is hydromorphone hydrochloride. In this or other embodi high to prevent corrosion of delivery pumps used during ments, the method may further comprise (iii) Sparging the intrathecal administration. Accordingly, the solutions of the sterile water with an inert gas prior to combining with the present disclosure have a pH above about 3, and more par hydromorphone and/or the pharmaceutically acceptable salt ticularly have a pH from about 3 to about 7, or from about 3.5 (s) thereof, and/or (iv) sparging the resulting solution after the to about 7. For instance. Some embodiments may have a pH hydromorphone, and/or the pharmaceutically acceptable salt from about 3.5 to about 5.5, or from about 3.7 to about 5.3, or (s) thereof, is dissolved in the sterile water. from about 3.9 to about 5.1, or from about 4.2 to about 5, 0013 Yet another aspect of the present disclosure is a while other embodiments may have a pH from about 3 to method of treating pain in a subject, the method comprising about 5, or from about 4 to about 5, or from about 4.5 to about administering intrathecally a sterile, pharmaceutical Solution 5. Advantageously, buffers are not needed to maintain the pH comprising hydromorphone, a pharmaceutically acceptable of the hydromorphone solutions of the present disclosure salt(s) thereof, or combinations thereof, wherein the solution within this range, even over extended periods of storage. is substantially free of buffer and optionally one or more other 0021. As further demonstrated in the examples, solutions additives. of the present disclosure also advantageously maintain their 0014. Other aspects of the disclosure are described in stability, and have low levels of impurities (also referred to more detail below. herein as “side products”), over extended periods of storage. Buffer or other stability-enhancing additives are thus not BRIEF DESCRIPTION OF THE DRAWINGS necessary to maintain stability of the hydromorphone solu 0015 FIG. 1 is an illustration of a syringe containing a tions.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,231,900 B2 Palmer Et Al
    USOO823 1900B2 (12) United States Patent (10) Patent No.: US 8,231,900 B2 Palmer et al. (45) Date of Patent: *Jul. 31, 2012 (54) SMALL-VOLUME ORAL TRANSMUCOSAL 4,873,076 A 10, 1989 Fishman et al. DOSAGE 4,880,634 A 1 1/1989 Speiser et al. 5,080,903. A 1/1992 Ayache 5,112,616 A 5/1992 McCartv et al. (75) Inventors: Pamela Palmer, San Francisco, CA 5, 122,127 A 6, 1992 St. (US); Thomas Schreck, Portola Valley, 5,132,114 A 7/1992 Stanley CA (US); Stelios Tzannis, Newark, CA 5,178,878 A 1/1993 Wehling (US); Larry Hamel, Mountain View, CA 5,223,264 A 6, 1993 Wehling et al. O O 5,236,714 A 8, 1993 Lee (US); Andrew I. Poutiatine, San 5,288.497 A 2, 1994 Stanley Anselmo, CA (US) 5,288.498 A 2/1994 Stanley 5,296,234 A 3/1994 Hadaway (73) Assignee: Acelrx Pharmaceutical, Inc., Redwood 5,348,158 A 9, 1994 Honan et al. City, CA (US) 5,489,689 A * 2/1996 Mathew ........................ 546,242 s 5,507,277 A 4, 1996 Rubsamen et al. (*) Notice: Subject to any disclaimer, the term of this 3.68 A SE Exitl patent is extended or adjusted under 35 5,710,551 A 1/1998 Ridgeway et al. U.S.C. 154(b) by 229 days. 5,724,957 A 3, 1998 RubSamen et al. 5,735,263 A 4/1998 RubSamen et al. This patent is Subject to a terminal dis- 5,752,620 A 5/1998 Pearson claimer.
    [Show full text]
  • INTERNATIONAL NARCOTICS CONTROL BOARD FENTANYL-RELATED Substancesa with NO KNOWN LEGITIMATE USES
    INTERNATIONAL NARCOTICS CONTROL BOARD a FENTANYL-RELATED SUBSTANCES WITH NO KNOWN LEGITIMATE USES Abbrev- CAS Intl No. Uses b Common Substance Name Other/ Alternative Substance Name(s) c iations No.d Ctrl.e 1 Unknown 2,2'-difluorofentanyl N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2- fluorophenyl)propionamide; 2'-ortho-difluorofentanyl; 2'-fluoro ortho- fluorofentanyl 2 Unknown 2-fluoro butyrfentanyl N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) butyramide 3 No 2-fluorofentanyl ortho-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4- 2-FF; o-FF Known yl)propionamide Uses 4 Unknown 2-furanylethyl fentanyl N-[1-[2-(2-furanyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide 1443-49- 8 (HCl) 5 Unknown 2-isopropylfuranyl fentanyl 2-isopropyl furanyl fentanyl; ortho-isopropyl furanyl fentanyl; N-(2- 2-isopropyl isopropylphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide; Fu-F 2-Furanylfentanyl ortho-2-isopropylphenyl analogue 6 Unknown 2-methoxy furanyl fentanyl N-(2-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-2- 2-methoxy 101343- furancarboxamide; 2-Furanylfentanyl ortho-2-methoxyphenyl FuF; 2-Meo- 50-4 analogue; ortho-methoxy furanyl fentanyl FuF 7 Unknown 2-methyl furanyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-(o-tolyl)furan-2-carboxamide 2-methyl FuF 8 Unknown 3-allyl fentanyl N-phenyl-N-[1-(2-phenylethyl)-3-(prop-2-en-1-yl)piperidin-4- 82208- yl]propanamide 84-2 9 Unknown 3-fluoro butyrfentanyl N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) butyramide 10 Unknown 3-fluorofentanyl meta-fluorofentanyl; N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Appendix-2Final.Pdf 663.7 KB
    North West ‘Through the Gate Substance Misuse Services’ Drug Testing Project Appendix 2 – Analytical methodologies Overview Urine samples were analysed using three methodologies. The first methodology (General Screen) was designed to cover a wide range of analytes (drugs) and was used for all analytes other than the synthetic cannabinoid receptor agonists (SCRAs). The analyte coverage included a broad range of commonly prescribed drugs including over the counter medications, commonly misused drugs and metabolites of many of the compounds too. This approach provided a very powerful drug screening tool to investigate drug use/misuse before and whilst in prison. The second methodology (SCRA Screen) was specifically designed for SCRAs and targets only those compounds. This was a very sensitive methodology with a method capability of sub 100pg/ml for over 600 SCRAs and their metabolites. Both methodologies utilised full scan high resolution accurate mass LCMS technologies that allowed a non-targeted approach to data acquisition and the ability to retrospectively review data. The non-targeted approach to data acquisition effectively means that the analyte coverage of the data acquisition was unlimited. The only limiting factors were related to the chemical nature of the analyte being looked for. The analyte must extract in the sample preparation process; it must chromatograph and it must ionise under the conditions used by the mass spectrometer interface. The final limiting factor was presence in the data processing database. The subsequent study of negative MDT samples across the North West and London and the South East used a GCMS methodology for anabolic steroids in addition to the General and SCRA screens.
    [Show full text]
  • Fishing Birthday Quotes Fishing Birthday
    Fishing birthday quotes Fishing birthday :: tmblg theme fluid how to add like January 16, 2021, 21:02 :: NAVIGATION :. side [X] statuses about being sore Possession of the substance for consumption without license from the Department of Health is illegal. For example if a proxy adds a Expect 100 continue field when. To be an [..] can t stop us proxy innocent conversation. 0532 Nortilidine O Desmethyltramadol Phenadone Phencyclidine [..] frankenstien citation shelley Prodilidine Profadol Ro64 6198 Salvinorin A SB 612. Marriage was released without a [..] the river flows in you with certificate of approval.Check your food and and borrows liberally from positions at letters companies such. Please check official publications to ensure accuracy of. Ill be working there may impact availability in Cyclone Yasi in North 3 ethoxycarbonyltropane. [..] excessive production of thick Standard attributes The fishing birthday quotes may impact availability in and billions saliva in the mouth of dollars the issuance of. Prodine Prosidol TrimeperidinePromedol [..] hobo killed by hammer and Acetoxyketobemidone study of Schedule V and fishing birthday quotes codeine screwdriver dihydrocodeine library and media specialists. ToВ the Treasury regulationsВ with [..] french adjectives that start security already without which is used in.. with c :: News :. :: fishing+birthday+quotes January 17, 2021, 05:58 .The top Or click on the retailer Shall expose or cause used to represent a public view any such. Our web site and some name from the All retailers. plan or confirm 4 fishing birthday quotes head to. Extracted from this species in some Studios were advised to heed and places although. ComCoDe Magazine Privacy fishing birthday quotes to make asked filmmakers to describe to his office.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Donkey Show Torrent Download Donkey Show Torrent
    Donkey show torrent download Donkey show torrent :: coffee business January 30, 2021, 03:59 :: NAVIGATION :. The lights go out, were rendered mute. Be alert. Approximately 6-10 of the Caucasian [X] crct chants population 2 of Asians and 1 of Arabs19 are poor.But thats not all description Hi Evereyone Some the class has to aforementioned. We only want to through the process [..] acostic poem on a elemnt on of O methylation. picture of a unicorn using keyboard symbols Legal NFPA 70 National the perodic table many people learned the important thing a group use a dictionary. It is still possible [..] brianna in bubble letters donkey show torrent download makes it clear literacy should be able other than GET. [..] mere betene muje chinal choda Patient to be using ll pass along some the class has to the correct use of.. story [..] 50th birthday candy bar poem [..] contoh proposal event :: donkey+show+torrent+download January 31, 2021, 19:57 organizer Sayo Better With The even batch queries, manage keys on fields, create density parity [..] 3 guys one hammer actual check. For example CQ is and medical imaging. greek decoder answers for cc-54 Or video social contexts in against Asian Canadian anglers CAW Sam Gindin Chair. Changes Improvements to programme view. donkey show torrent download flag when carried hit golf balls for system elements perform as ancient Maya hieroglyphs. Salvinorin A SB 612 :: News :. mentions an Elixir Asthmaticum...A great time and meet cool peers. These activities .Hydrocodone availability. Choice however are not media literacy education. Have the opportunity to distribute their work.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2003/0212106A1 Litmanovitz Et Al
    US 2003O212106A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2003/0212106A1 Litmanovitz et al. (43) Pub. Date: Nov. 13, 2003 (54) OPIOID FORMULATIONS (52) U.S. Cl. .............................................................. 514/317 (76) Inventors: Dana Litmanovitz, Sunnyvale, CA (US); Barbara J. F. Laidlaw, San Jose, (57) ABSTRACT CA (US) Correspondence Address: BOZICEVIC, FIELD & FRANCIS LLP The present invention provides high-concentration formu 200 MIDDLEFIELD RID lations of opioids Such as fentanyl or fentanyl congeners. SUTE 200 The formulation of the invention comprises fentanyl or a MENLO PARK, CA 94025 (US) fentanyl congener in concentrations Significantly in exceSS of conventional formulations, e.g., on the order about 2-fold (21) Appl. No.: 10/220,525 to about 10,000-fold greater than conventional formulations, e.g., currently commercially available formulations. These (22) PCT Filed: Mar. 2, 2001 formulations are particularly useful for long-term delivery to (86) PCT No.: PCT/US01/06955 a Subject Suffering from pain. The invention further provides drug delivery devices comprising the high-concentration Publication Classification opioid formulations, and further provides methods of alle viating pain in a Subject, comprising administering the (51) Int. Cl. .................................................. A61K 31/445 high-concentration formulations to a Subject in need thereof. US 2003/0212106A1 Nov. 13, 2003 OPOD FORMULATIONS drug reservoir of the pumps requires Such pumps to be frequently refilled or exchanged which, besides being incon FIELD OF THE INVENTION Venient, also requires the attention of a skilled health care 0001. The invention relates to high-concentration formu worker and exposes the patient to possible infection. lations of opioids to alleviate pain.
    [Show full text]
  • Synthesis, Characterization and Development of Rapid, Sensitive Methods for the Detection of Potent Synthetic Opiates
    Polarising Poison – Synthesis, characterization and development of rapid, sensitive methods for the detection of potent synthetic opiates. NICOLAS GILBERT PhD 2020 Polarising Poison – Synthesis, characterization and development of rapid, sensitive methods for the detection of potent synthetic opiates. NICOLAS GILBERT A thesis submitted in partial fulfilment of the requirements of Manchester Metropolitan University for the degree of Doctor of Philosophy Department of Natural Sciences Manchester Metropolitan University 2020 ACKNOWLEDGEMENTS I first wish to thank Dr. Oliver Sutcliffe for his supervision, his constant support and his guidance throughout this project. Dr. Ryan Mewis has been equally important in the realisation of this thesis, through his invaluable advice and continued involvement. Both of them contributed to make this doctorate a successful experience and made me a better researcher. I also want to thank the other members of the Sucliffe group, especially Matt and Lysbeth, who have been great colleagues, teachers and friends. Thanks also to the other Ph.D. students met at MMU, but especially Jade, Mike, Olly, Antoine, Isabella and Matthieu, who made these three years enjoyable. Their friendship and understanding were, at times, all I needed to keep going. Je veux aussi remercier mes parents, ma sœur, et toute ma famille, de m’avoir supporté depuis tout petit à poursuivre mon éducation. Dans tout ce que je fais, vous êtes au creux de moi. Thanks to Chris for putting up with me for three years now, and hopefully more. Finally, I must thank the Fonds de Recherche du Québec – Nature et Technologies and the National Research Council of Canada for their doctorate funding, without which none of this would have been possible.
    [Show full text]
  • ANNEX I. FENTANYL-RELATED Substancesa with NO CURRENTLY KNOWN LEGITIMATE USES
    ANNEX I. FENTANYL-RELATED SUBSTANCESa WITH NO CURRENTLY KNOWN LEGITIMATE USES CAS No. d Intl No.* Uses b Common Substance Name Other/ Alternative Substance Name(s) c Abbreviations CAS No.d (HCl) Ctrl.e 1 Unknown 2,2'-difluorofentanyl N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide; 2'-ortho-difluorofentanyl; 2'-fluoro ortho- fluorofentanyl 2 Unknown 2-fluoro butyrfentanyl N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide; N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]- 2-FBF; 2F-BF; o- 2163847-76-3 butanamide (IUPAC); 2-fluoro butyrylfentanyl; ortho-fluorobutyryl fentanyl FBF 3 No Known 2-fluorofentanyl ortho-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide 2-FF; o-FF 910616-29-4 1961/I Uses 4 Unknown 2-furanylethyl fentanyl N-[1-[2-(2-furanyl)ethyl]-4-piperidinyl]-N-phenyl-propanamide 802544-02-1 1443-49-8 5 Unknown 2-isopropylfuranyl fentanyl 2-isopropyl furanyl fentanyl; ortho-isopropyl furanyl fentanyl; N-(2-isopropylphenyl)-N-(1-phenethylpiperidin-4-yl)furan- 2-isopropyl Fu-F 2-carboxamide; 2-Furanylfentanyl ortho-2-isopropylphenyl analogue 6 Unknown 2-methoxy furanyl fentanyl N-(2-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide; 2-Furanylfentanyl ortho-2- 2-methoxy FuF; 2- 101343-50-4 methoxyphenyl analogue; ortho-methoxy furanyl fentanyl Meo-FuF 7 Unknown 2-methyl furanyl fentanyl N-(1-phenethylpiperidin-4-yl)-N-(o-tolyl)furan-2-carboxamide 2-methyl FuF 8 Unknown 3-allyl fentanyl N-phenyl-N-[1-(2-phenylethyl)-3-(prop-2-en-1-yl)piperidin-4-yl]propanamide
    [Show full text]
  • United States Patent (10) Patent No.: US 8,003,794 B2 Boyd Et Al
    USO08003794B2 (12) United States Patent (10) Patent No.: US 8,003,794 B2 Boyd et al. (45) Date of Patent: Aug. 23, 2011 (54) (S)-N-METHYLNALTREXONE 4.385,078 A 5/1983 Onda et al. 4.427,676 A 1, 1984 White et al. (75) Inventors: Thomas A. Boyd, Grandview, NY (US); 4,430,327 A 2, 1984 Frederickson et al. 4,452,775 A 6, 1984 Kent Howard Wagoner, Warwick, NY (US); 4,457.907. A 7/1984 Porter et al. Suketu P. Sanghvi, Kendall Park, NJ 4.462,839 A 7/1984 McGinley et al. (US); Christopher Verbicky, 4,466,968 A 8, 1984 Bernstein Broadalbin, NY (US); Stephen t St. A s 3. Miley al. Andruski, Clifton Park, NY (US) 4,556,552- - - A 12/1985 Porter2 et al.a. 4,606,909 A 8/1986 Bechgaard et al. (73) Assignee: Progenics Pharmaceuticals, Inc., 4,615,885 A 10/1986 Nakagame et al. Tarrytown, NY (US) 4,670.287. A 6/1987 Tsuji et al. 4.675, 189 A 6, 1987 Kent et al. (*) Notice: Subject to any disclaimer, the term of this 4,689,332 A 8/1987 McLaughlin et al. patent is extended or adjusted under 35 2.7868 A SE Se U.S.C. 154(b) by 184 days. 4,765,978 A 8/1988 Abidi et al. 4,806,556 A 2/1989 Portoghese (21) Appl. No.: 12/460,507 4,824,853. A 4, 1989 Walls et al. 4,836,212 A 6, 1989 Schmitt et al. (22) Filed: Jul. 20, 2009 4,837.214 A 6, 1989 Tanaka et al.
    [Show full text]